Novel Anti-Inflammatories for Cardiopulmonary Bypass

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,485,330.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44HL080934-02
Award Id:
75766
Agency Tracking Number:
HL080934
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NOVELMED THERAPEUTICS, INC., 2265 ENTERPRISE PKWY, TWINSBURG, OH, 44087
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
190155171
Principal Investigator:
() -
Business Contact:
() -
rekha@novelmed.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): There is evidence that the complement alternative pathway (AP) contributes significantly to the generation of pro-inflammatory agents in post-CPB inflammation. Complement activation products such as C3a, C5a, and C5b-9 have been found in blood samples of patients undergoing bypass. NovelMed has identified a murine monoclonal antibody to factor B which prevents complement and cellular activation. The antibody also prevents the elastase and TNF production. Murine monoclona l antibodies can not be used as therapeutics due to Human Anti Mouse Antibody (HAMA) response. In this phase II proposal we propose to convert the murine monoclonal into a humanized version of the monoclonal. NovelMed currently has three patents pending on the factor B monoclonal antibodies. The phase II studies should result in an Investigational New Drug (IND) application for the treatment of inflammatory conditions. PUBLIC HEALTH RELEVANCE: Currently there is no FDA approved therapeutic for down regulati ng inflammation in bypass. NovelMed's lead drug BikajuMabTM inhibits C3a, C5a, C5b-9 formation. As a result, activation of neutrophils, monocytes, and platelets is also prevented. In addition BikazuMabTM inhibits TNF-alpha and elastase production, major ha ll mark of inflammatory conditions. Humanized version of the monoclonal is expected to produce similar results and thus provide patient benefit in cardiopulmonary bypass.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government